475 related articles for article (PubMed ID: 9649918)
21. [Study on the indication of surgical resection of pulmonary metastasis of malignant trophoblastic tumor].
Zhang Y; Xiang Y; Ren T; Wan XR; Yang XY
Zhonghua Fu Chan Ke Za Zhi; 2005 Feb; 40(2):83-6. PubMed ID: 15840284
[TBL] [Abstract][Full Text] [Related]
22. Menstrual bleeding patterns in Norplant-2 implant users.
Biswas A; Leong WP; Ratnam SS; Viegas OA
Contraception; 1996 Aug; 54(2):91-5. PubMed ID: 8842585
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of combined use of ultrasonography and beta-hCG determination in diagnosis of pelvic lesions of malignant trophoblastic disease].
Fu QZ; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):352-4, 383-4. PubMed ID: 2178083
[TBL] [Abstract][Full Text] [Related]
24. Absence of chorionic gonadotropin in sera of women who use intrauterine devices.
Segal SJ; Alvarez-Sanchez F; Adejuwon CA; Brache de Mejia V; Leon P; Faundes A
Fertil Steril; 1985 Aug; 44(2):214-8. PubMed ID: 4018277
[TBL] [Abstract][Full Text] [Related]
25. Use of Norplant implants in a New York City clinic population.
Gerber S; Westhoff C; Lopez M; Gordon L
Contraception; 1994 Jun; 49(6):557-64. PubMed ID: 8070260
[TBL] [Abstract][Full Text] [Related]
26. Choriocarcinoma following ovarian hydatidiform mole: a case report.
Joneborg U; Papadogiannakis N; Lindell G; Marions L
J Reprod Med; 2011; 56(11-12):511-4. PubMed ID: 22195336
[TBL] [Abstract][Full Text] [Related]
27. Serum SP1, hPL and beta-hCG levels in trophoblastic diseases.
Zhang WY; Yen GL
Chin Med J (Engl); 1991 Dec; 104(12):995-8. PubMed ID: 1723674
[TBL] [Abstract][Full Text] [Related]
28. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.
Sivin I; Campodonico I; Kiriwat O; Holma P; Diaz S; Wan L; Biswas A; Viegas O; el din Abdalla K; Anant MP; Pavez M; Stern J
Hum Reprod; 1998 Dec; 13(12):3371-8. PubMed ID: 9886517
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic reliability of simultaneous measurements of beta human chorionic gonadotropin and pregnancy-specific beta-1-glycoprotein in serum of patients with trophoblastic disease.
Takayama M; Soma H; Isaka K; Okudera K; Ogawa T; Kikuchi K
Gynecol Obstet Invest; 1987; 23(3):151-6. PubMed ID: 3036671
[TBL] [Abstract][Full Text] [Related]
30. Return of fertility following discontinuation of Norplant-II subdermal implants. ICMR Task Force on Hormonal Contraception.
Buckshee K; Chatterjee P; Dhall GI; Hazra MN; Kodkany BS; Lalitha K; Logambal A; Manchanda P; Nanda UK; RaiChoudhury G
Contraception; 1995 Apr; 51(4):237-42. PubMed ID: 7796589
[TBL] [Abstract][Full Text] [Related]
31. Continuation rates of long-acting methods of contraception. A comparative study of Norplant implants and intrauterine devices.
Fleming D; Davie J; Glasier A
Contraception; 1998 Jan; 57(1):19-21. PubMed ID: 9554246
[TBL] [Abstract][Full Text] [Related]
32. Human chorionic gonadotropin and its subunits in hydatidiform mole and choriocarcinoma.
Dawood MY; Saxena BB; Landesman R
Obstet Gynecol; 1977 Aug; 50(2):172-81. PubMed ID: 195242
[TBL] [Abstract][Full Text] [Related]
33. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
[TBL] [Abstract][Full Text] [Related]
34. Gestational trophoblastic diseases: the ratio of choriogonadotropin to specific pregnancy protein, hCG/SP1, provides useful diagnostic and prognostic evidence.
Szymendera JJ; Ploch E; Zalucka K; Sikorowa L; Kaminska JA; Gadek A
Gynecol Oncol; 1986 Feb; 23(2):149-59. PubMed ID: 3002918
[TBL] [Abstract][Full Text] [Related]
35. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
36. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.
Kaewrudee S; Taneepanichskul S; Jaisamraun U; Reinprayoon D
Contraception; 1999 Jul; 60(1):25-30. PubMed ID: 10549449
[TBL] [Abstract][Full Text] [Related]
37. The secretion of human chorionic gonadotropin-like substance in women employing contraceptive measures.
Huang SC; Chen HC; Chen RJ; Hsieh CY; Wei PY; Ouyang PC
J Clin Endocrinol Metab; 1984 Apr; 58(4):646-53. PubMed ID: 6699130
[TBL] [Abstract][Full Text] [Related]
38. Plasma beta-subunit human chorionic gonadotropin assay in molar pregnancy and choriocarcinoma.
Yuen BH; Cannon W; Benedet JL; Boyes DA
Am J Obstet Gynecol; 1977 Apr; 127(7):711-2. PubMed ID: 557901
[TBL] [Abstract][Full Text] [Related]
39. Choriocarcinoma with negative urinary and serum beta human chorionic gonadotropin (betaHCG)--a case report.
Mehra R; Huria A; Gupta P; Mohan H
Indian J Med Sci; 2005 Dec; 59(12):538-41. PubMed ID: 16385173
[TBL] [Abstract][Full Text] [Related]
40. Change in human chorionic gonadotropin in gestational trophoblastic disease observed during the course of chemotherapy.
Huang SC; Hsieh CY; Ouyang PC
J Formos Med Assoc; 1991 Jan; 90(1):53-8. PubMed ID: 1679110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
